The National Academies of Sciences, Engineering, and Medicine (NASEM) is pushing the US government – including the US Food and Drug Administration and National Institutes of Health – to do more to improve the representation of underrepresented populations in clinical trials.
With the support from the National Institutes of Health, NASEM produced a new report recommending “system-level actions” for improving...